The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
The Role of Tumoral FOXP3 on Cell Proliferation, Migration, and Invasion in Gastric Cancer
Zhang, L., Xu, J., Zhang, X., Zhang, Y., Wang, L., Huang, X., & Xu, Z. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479442 · Cited by 4,088
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Takahashi, T., Kuniyasu, Y., Toda, M., Sakaguchi, N., Itoh, M., Iwata, M., Shimizu, J., & Sakaguchi, S. (1998) · International Immunology · doi:10.1093/intimm/10.12.1969 · Cited by 1,568
Liyanage, U. K., Moore, T. T., Joo, H.-G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.5.2756 · Cited by 1,467
Jonuleit, H., Schmitt, E., Stassen, M., Tuettenberg, A., Knop, J., & Enk, A. H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.11.1285 · Cited by 1,255
Sutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Dannull, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25947 · Cited by 989
CTLA-4: new insights into its biological function and use in tumor immunotherapy
Egen, J. G., Kuhns, M. S., & Allison, J. P. (2002) · Nature Immunology · doi:10.1038/ni0702-611 · Cited by 940
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., et al. (2001) · Blood · doi:10.1182/blood.v98.1.210 · Cited by 913
Self-citationEfficacy of Lenalidomide in Myelodysplastic Syndromes
List, A., Kurtin, S., Roe, D. J., Buresh, A., Mahadevan, D., Fuchs, D., Rimsza, L., Heaton, R., Knight, R., & Zeldis, J. B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041668 · Cited by 880
Ghiringhelli, F., Larmonier, N., Schmitt, E., Parcellier, A., Cathelin, D., Garrido, C., Chauffert, B., Solary, E., Bonnotte, B., & Martin, F. (2004) · European Journal of Immunology · doi:10.1002/eji.200324181 · Cited by 880
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. B., Dredge, K., & Dalgleish, A. G. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1323 · Cited by 809
Self-citationZorn, E., Nelson, E. A., Mohseni, M., Porcheray, F., Kim, H., Litsa, D., Bellucci, R., Raderschall, E., Canning, C., Soiffer, R. J., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004747 · Cited by 740
Beyer, M., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2006-02-002774 · Cited by 732
Mitsiades, N., Mitsiades, C. S., Poulaki, V., Chauhan, D., Richardson, P. G., Hideshima, T., Munshi, N. C., Treon, S. P., & Anderson, K. C. (2002) · Blood · doi:10.1182/blood.v99.12.4525 · Cited by 669
Increase of regulatory T cells in the peripheral blood of cancer patients.
Wolf, A. M., Wolf, D. G. F., Steurer, M., Gastl, G., Gunsilius, E., & Grubeck-Loebenstein, B. (2003) · PubMed · Cited by 655
Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.376 · Cited by 609
Haslett, P. A. J., Corral, L. G., Albert, M., & Kaplan, G. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.11.1885 · Cited by 573
Scurfin (FOXP3) Acts as a Repressor of Transcription and Regulates T Cell Activation
Schubert, L. A., Jeffery, E., Zhang, Y., Ramsdell, F., & Ziegler, S. F. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m104521200 · Cited by 548
Bettelli, E., Dastrange, M., & Oukka, M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501675102 · Cited by 545
Large-scale in vitro expansion of polyclonal human CD4+CD25high regulatory T cells
Hoffmann, P., Eder, R., Kunz-Schughart, L. A., Andreesen, R., & Edinger, M. (2004) · Blood · doi:10.1182/blood-2004-01-0086 · Cited by 494
Ichihara, F., Kono, K., Takahashi, A., Kawaida, H., Sugai, H., & Fujii, H. (2003) · PubMed · Cited by 489
Valzasina, B., Guiducci, C., Dislich, H., Killeen, N., Weinberg, A. D., & Colombo, M. P. (2005) · Blood · doi:10.1182/blood-2004-07-2959 · Cited by 428
Yang, Z.-Z., Novak, A. J., Stenson, M. J., Witzig, T. E., & Ansell, S. M. (2006) · Blood · doi:10.1182/blood-2005-08-3376 · Cited by 420
Hayashi, T., Hideshima, T., Akiyama, M., Podar, K., Yasui, H., Raje, N., Kumar, S., Chauhan, D., Treon, S. P., Richardson, P., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05286.x · Cited by 323
Schey, S. A., Fields, P., Bartlett, J. B., Clarke, I. A., Ashan, G., Knight, R. D., Streetly, M., & Dalgleish, A. G. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.052 · Cited by 314
Self-citationDistinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells
Takeda, I., Ine, S., Killeen, N., Ndhlovu, L. C., Murata, K., Satomi, S., Sugamura, K., & Ishii, N. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.6.3580 · Cited by 308
Beyer, M., Kochanek, M., Giese, T., Endl, E., Weihrauch, M. R., Knolle, P. A., Classen, S., & Schultze, J. L. (2006) · Blood · doi:10.1182/blood-2005-09-3671 · Cited by 301
Foxp3: a critical regulator of the development and function of regulatory T cells
Hori, S., & Sakaguchi, S. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.02.020 · Cited by 291
Hirahara, K., Liu, L., Clark, R. A., Yamanaka, K.-I., Fuhlbrigge, R. C., & Kupper, T. S. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.7.4488 · Cited by 291
Golgher, D., Jones, E., Powrie, F., Elliott, T., & Gallimore, A. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11<3267::aid-immu3267>3.0.co;2-1 · Cited by 282
Chang, D. H., Liu, N., Klimek, V., Hassoun, H., Mazumder, A., Nimer, S. D., Jagannath, S., & Dhodapkar, M. V. (2006) · Blood · doi:10.1182/blood-2005-10-4184 · Cited by 271
Valzasina, B., Piconese, S., Guiducci, C., & Colombo, M. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4217 · Cited by 259
Regulatory T cells: Development, function and role in autoimmunity
LAN, R., ANSARI, A., LIAN, Z., & GERSHWIN, M. (2005) · Autoimmunity Reviews · doi:10.1016/j.autrev.2005.01.007 · Cited by 224
Trzonkowski, P., Szmit, E., Myśliwska, J., Dobyszuk, A., & Myśliwski, A. (2004) · Clinical Immunology · doi:10.1016/j.clim.2004.04.003 · Cited by 223
Jones, E., Dahm‐Vicker, M., Simon, A. K., Green, A., Powrie, F. M., Cerundolo, V., & Gallimore, A. (2002) · PubMed · Cited by 208
Nocentini, G., & Riccardi, C. (2005) · European Journal of Immunology · doi:10.1002/eji.200425818 · Cited by 179
Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo
Lentzsch, S., LeBlanc, R., Podar, K., Davies, F., Lin, B., Hideshima, T., Catley, L., Stirling, D. I., & Anderson, K. C. (2003) · Leukemia · doi:10.1038/sj.leu.2402745 · Cited by 162
Self-citationDredge, K., Marriott, J. B., Todryk, S. M., Muller, G. W., Chen, R., Stirling, D. I., & Dalgleish, A. G. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.10.4914 · Cited by 162
Self-citationMarriott, J. B., Clarke, I., Dredge, K. S., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · Clinical & Experimental Immunology · doi:10.1046/j.1365-2249.2002.01954.x · Cited by 155
Self-citationClinical pharmacokinetics of thalidomide
Teo, S. K., Colburn, W. A., Tracewell, W. G., Kook, K. A., Stirling, D. I., Jaworsky, M. S., Scheffler, M. A., Thomas, S. D., & Laskin, O. L. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443050-00004 · Cited by 150
Self-citationBartlett, J. B., Michael, A., Clarke, I., Dredge, K. S., Nicholson, S., Kristeleit, H., Polychronis, A., Pandha, H. S., Muller, G. W., Stirling, D., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601579 · Cited by 143
Self-citationStreetly, M. J., Gyertson, K., Daniel, Y., Zeldis, J. B., Kazmi, M. A., & Schey, S. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07013.x · Cited by 132
Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo
Antony, P. A., Paulos, C. M., Ahmadzadeh, M., Akpınarlı, A., Palmer, D. C., Sato, N., Kaiser, A., Hinrichs, C. S., Klebanoff, C. A., Tagaya, Y., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.9.5255 · Cited by 131
Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells
Wei, W., Morris, G. P., & Kong, Y.-C. M. (2003) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-003-0444-1 · Cited by 124
Clinical Experience With Denileukin Diftitox (ONTAK)
Foss, F. M. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.12.017 · Cited by 116
Dimopoulos, M. A., Spencer, A. G., Attal, M., Prince, M., Harousseau, J., Dmoszyńska, A., Yu, Z., Olesnyckyj, M., Zeldis, J. B., & Knight, R. (2005) · Blood · doi:10.1182/blood.v106.11.6.6 · Cited by 113
Motta, M., Rassenti, L. Z., Shelvin, B., Lerner, S. A., Kipps, T. J., Keating, M. J., & Wierda, W. G. (2005) · Leukemia · doi:10.1038/sj.leu.2403907 · Cited by 107
Chanan-Khan, A. A., Miller, K. C., Takeshita, K., Koryzna, A., Donohue, K. A., Bernstein, Z. P., Mohr, A., Klippenstein, D. L., Wallace, P. K., Zeldis, J. B., et al. (2005) · Blood · doi:10.1182/blood-2005-02-0669 · Cited by 104
Thalidomide and a Thalidomide Analogue Drug Costimulate Virus‐Specific CD8+T Cells In Vitro
Haslett, P. A. J., Hanekom, W. A., Muller, G. W., & Kaplan, G. (2003) · The Journal of Infectious Diseases · doi:10.1086/368126 · Cited by 93
Self-citationDo CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?
Antony, P. A., & Restifo, N. P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00002 · Cited by 69
A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T. M., Figg, W. D., & Royce, C. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1546 · Cited by 69
Calmels, B., Paul, S., Futin, N., Ledoux, C., Stoeckel, F., & Acres, B. (2004) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700781 · Cited by 65
Koh, K.-R., Janz, M., Mapara, M. Y., Lemke, B., Stirling, D., Dörken, B., Zenke, M., & Lentzsch, S. (2004) · Blood · doi:10.1182/blood-2004-03-0828 · Cited by 57
Self-citationThalidomide-derived immunomodulatory drugs as therapeutic agents
Galustian, C., Labarthe, M., Bartlett, J. B., & Dalgleish, A. G. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.12.1963 · Cited by 50
Self-citationImmune regulation in tumor-bearing hosts
Baecher‐Allan, C., & Anderson, D. E. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.010 · Cited by 49
Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells.
Loke, P., & Allison, J. P. (2004) · Arthritis Research · doi:10.1186/ar1225 · Cited by 34
Diederichsen, A., Zeuthen, J., Christensen, P. B., & Kristensen, T. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00033-7 · Cited by 33
Hoen, E. N. M. N., Wagenaar-Hilbers, J. P. A., Boot, E. P. J., Lin, C., Arkesteijn, G. J. A., van Eden, W., Taams, L. S., & Wauben, M. H. M. (2004) · European Journal of Immunology · doi:10.1002/eji.200324725 · Cited by 25
Querfeld, C., Kuzel, T. M., Guitart, J., & Rosen, S. T. (2005) · Blood · doi:10.1182/blood.v106.11.3351.3351 · Cited by 21
Cited by
Rapoport, A. P., Stadtmauer, E. A., Binder-Scholl, G. K., Goloubeva, O., Vogl, D. T., Lacey, S. F., Badros, A. Z., Garfall, A., Weiss, B., Finklestein, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3910 · Cited by 856
T-Regulatory Cells: Key Players in Tumor Immune Escape and Angiogenesis
Facciabene, A., Motz, G. T., & Coukos, G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3687 · Cited by 821
Gandhi, A. K., Kang, J., Havens, C. G., Conklin, T., Ning, Y., Wu, L., Ito, T., Ando, H., Waldman, M. F., Thakurta, A., et al. (2014) · British Journal of Haematology · doi:10.1111/bjh.12708 · Cited by 619
Self-citationMechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma
Quach, H., Ritchie, D., Stewart, A. K., Neeson, P., Harrison, S., Smyth, M. J., & Prince, H. M. (2010) · Leukemia · doi:10.1038/leu.2009.236 · Cited by 600
Targeting the bone marrow microenvironment in multiple myeloma
Kawano, Y., Moschetta, M., Manier, S., Glavey, S., Görgün, G. T., Roccaro, A. M., Anderson, K. C., & Ghobrial, I. M. (2015) · Immunological Reviews · doi:10.1111/imr.12233 · Cited by 391
Metadata
- Authors
- Galustian, C., Meyer, B., Labarthe, M.-C., Dredge, K., Klaschka, D., Henry, J., Todryk, S., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J. B., & Dalgleish, A. G.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2008-11-14
- Volume
- 58
- Issue
- 7
- Pages
- 1033-1045
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1999088487
- Cited by
- 391
- References
- 64
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.